Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Interest-Expense" stands at 1.12 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Novartis AG's third quarter result of 0.281 Billion USD for the item "Interest Expense" represents a decrease of -5.93 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 0.281 Billion USD for the item "Interest Expense" represents an increase of 3.25 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 1.12 Billion USD for the item "Interest Expense" represents an increase of 0.8 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 14.67 percent compared to the value the year prior.
The 1 year change in percent is 14.67.
The 3 year change in percent is 37.68.
The 5 year change in percent is 27.93.
The 10 year change in percent is 63.64.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Interest Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Interest Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Interest Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Interest Expense | 280,205,508,085.11 |